Device Trial Radar · NCT07059962
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Sep 9, 2025
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Bodyport Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 11, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.
Conditions
- Kidney Disease
- Peritoneal Dialysis (PD)
- End Stage Kidney Disease (ESRD)
Interventions
Bodyport Cardiac ScaleDevice
The Bodyport Cardiac Scale captures several physiological signals, which are used to derive multiple biomarkers that reflect a user's hemodynamic and fluid status.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity AnalysisTime frame: 1 year
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Desert Cities Dialysis
Victorville, California · Recruiting
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.